Option chain shows key data for Pharvaris's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Pharvaris.

Pharvaris (NASDAQ:PHVS) Stock, Option Chain

Pharvaris

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

PHVS

Biotech

News

Health Care

General

Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment.

FDA Clears Pharvaris&#39; Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

Markets

Trading Ideas

MLGO

OPTN

SERA

YEXT

U.S. stocks traded mixed toward the end of trading on Wednesday.

The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&amp;P 500 also fell, dropping, 0.05% to 4,564.73.

Gold Moves Higher; Campbell Soup Earnings Top Expectations

Movers

AAOI

ALLR

ARVN

ASAN

ASPN

AVAV

BCRX

CANO

CHSN

CJET

CLIN

CZOO

FLNC

GBNH

JNVR

LEJU

LGHL

LOVE

MESA

NRSN

NVNI

PHIO

PLAY

POWL

RELI

RENT

SFIX

SOAR

TGTX

WBUY

Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results.

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

Pharvaris NV

Press Releases

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

Axonis Therapeutics Announces $115 Million Series A Financing

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Pharvaris Outlines 2025 Strategic Priorities

Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025

Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission

Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Comments

Pharvaris

Pharvaris (PHVS) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell